# US 2026/0085113 A1 · All-in-one agonistic antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085113 A1
- Document ID: US20260085113A1
- Status: Published application
- Kind: A1
- Application number: 19/348,515
- Filed: 2025-10-02
- Published: 2026-03-26
- Earliest claimed: 2023-04-03
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Petra Elisabeth Marilena BALBI; Jack Anthony BATES; Samuele CALABRO; Laura CODARRI DEAK; Stephan GASSER; Guy GEORGES; Xavier GUERIPEL; Ralf Joerg HOSSE; Christian KLEIN; Stéphane Gérard Alain LECLAIR; Ekkehard MOESSNER; Christian MUELLER; Diana Angela PIPPIG; Laurene POUSSE; Camilla Elizabeth TREVOR; Pablo UMAÑA FERNÁNDEZ
- Web page: https://patentgrep.com/patent/US20260085113A1

## CPC

- C07K 16/246: {IL-2}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 35/00: Antineoplastic agents
- C07K 16/244: {Interleukins [IL]}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/40: against enzymes
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/522: CH1 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/75: Agonist effect on antigen
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The application relates to antigen binding molecules comprising a pair of biparatopic target-binding domains, a pair of cytokine receptor-binding domains and an Fc domain, wherein the target-binding domains simultaneously bind the target antigen and the cytokine receptor-binding domains bind subunits of a cytokine receptor complex. Biparatopic assembly of the cytokine receptor-binding domains in presence of the target antigen allows to selectively activate cytokine receptors and effectively mimic cytokine activity in a targeted manner.

## Claims

### Claim 1

An antigen binding molecule comprising
i) a first target-binding domain,
ii) a second target-binding domain,
iii) a first cytokine receptor-binding domain,
iv) a second cytokine receptor-binding domain, and
v) a Fc domain,
wherein the first target-binding domain is capable of binding a first epitope on the target antigen and the second target-binding domain is capable of binding a second epitope on the target antigen, wherein the first and the second target-binding domains do not compete for binding on the tumor-associated antigen; and
wherein the first cytokine receptor-binding domain is capable of binding a first cytokine receptor subunit and the second cytokine receptor-binding domain is capable of binding a second cytokine receptor subunit.

### Claim 2 (depends on 1)

The antigen binding molecule according to claim 1, wherein first and second target-binding domains are antibody fragments, particularly Fv, Fab, scFv, scFab or single domain antibodies.

### Claim 3 (depends on 1)

The antigen binding molecule according to claim 1, wherein the first and second target-binding domain are Fab molecules, wherein the first target-binding domain comprises a heavy chain variable domain (VH1), a light chain variable domain (VL1), a heavy chain constant domain (CH11) and a light chain constant domain (CL1) and the second target-binding domain comprises a heavy chain variable domain (VH2), a light chain variable domain (VL2), a heavy chain constant domain (CH12) and a light chain constant domain (CL2).

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The antigen binding molecule according to claim 1, wherein the first target-binding domain and/or the second target-binding domain is a cross-Fab molecule.

### Claim 6 (depends on 1)

The antigen binding molecule according to claim 1, wherein the first target-binding domain and/or the second target-binding domain comprise charge mutations.

### Claim 7 (depends on 1)

The antigen binding molecule according to claim 1, wherein the first target-binding domain is a cross-Fab and the second target-binding domain comprises charge mutations or wherein the second target-binding domain is a cross-Fab and the first target-binding domain comprises charge mutations.

### Claim 8 (depends on 1)

The antigen binding molecule according to claim 1, wherein the first target-binding domain and the second target-binding domain specifically bind to a tumor-associated antigen or a T cell antigen.

### Claim 9 (depends on 1)

The antigen binding molecule according to claim 1, wherein the first target-binding domain and the second target-binding domain specifically bind to FAP, PD-1, Her2, Her3, LAG-3, CEA or EGFR.

### Claim 10 (depends on 1)

The antigen binding molecule according to claim 1, wherein
a) the first target-binding domain comprises a VH1 of SEQ ID NO: 20 and a VL1 of SEQ ID NO: 21 and the second target-binding domain comprises a VH2 of SEQ ID NO: 22 and a VL2 of SEQ ID NO: 23, or
b) the first target-binding domain comprises a VH1 of SEQ ID NO: 22 and a VL1 of SEQ ID NO: 23 and the second target-binding domain comprises a VH2 of SEQ ID NO: 20 and a VL2 of SEQ ID NO: 21, or
c) the first target-binding domain comprises a VH1 of SEQ ID NO: 80 and a VL1 of SEQ ID NO: 81 and the second target-binding domain comprises a VH2 of SEQ ID NO: 82 and a VL2 of SEQ ID NO: 83, or
d) the first target-binding domain comprises a VH1 of SEQ ID NO: 82 and a VL1 of SEQ ID NO: 83 and the second target-binding domain comprises a VH2 of SEQ ID NO: 80 and a VL2 of SEQ ID NO: 81; or
e) the first target-binding domain comprises a VH1 of SEQ ID NO: 82 and a VL1 of SEQ ID NO: 83 and the second target-binding domain comprises a VH2 of SEQ ID NO: 140 and a VL2 of SEQ ID NO: 141; or
f) the first target-binding domain comprises a VH1 of SEQ ID NO: 140 and a VL1 of SEQ ID NO: 141 and the second target-binding domain comprises a VH2 of SEQ ID NO: 82 and a VL2 of SEQ ID NO: 83.

### Claim 11 (depends on 1)

The antigen binding molecule according to claim 1, wherein both the first and second cytokine receptor subunits are subunits of the IFNγ receptor complex or IL-2 receptor complex.

### Claim 12 (depends on 1)

The antigen binding molecule according to claim 1, wherein
a) the first cytokine receptor-binding domain is capable of binding IFNγR1 and the second cytokine receptor-binding domain is capable of binding IFNγR2, or
b) the first cytokine receptor-binding domain is capable of binding IFNγR2 and the second cytokine receptor-binding domain is capable of binding IFNγR1;
c) the first cytokine receptor-binding domain is capable of binding IL-2Rβ and the second cytokine receptor-binding domain is capable of binding IL-2Rγ; or
d) the first cytokine receptor-binding domain is capable of binding IL-2Rγ and the second cytokine receptor-binding domain is capable of binding IL-2Rβ.

### Claim 13 (depends on 1)

The antigen binding molecule according to claim 1, wherein the first and second cytokine receptor-binding domains are antibody fragments, particularly Fv, Fab, scFv, scFab, single domain antibodies or VHH domains.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The antigen binding molecule according to claim 1, wherein
a) the first cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 5, and the second cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 9, or
b) the first cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 9, and the second cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 5; or
c) the first cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62 and SEQ ID NO: 64, and the second cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68 and SEQ ID NO: 69, or
d) the first cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68 and SEQ ID NO: 69, and the second cytokine receptor-binding domain comprises an amino acid sequence selected from SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62 and SEQ ID NO: 64.

### Claim 16 (depends on 1)

The antigen binding molecule according to claim 1, wherein the Fc domain comprises a first Fc domain subunit and a second Fc domain subunit.

### Claim 17 (depends on 1)

The antigen binding molecule according to claim 1, wherein the Fc domain is an IgG, particularly an IgG1, Fc domain.

### Claim 18 (depends on 1)

The antigen binding molecule according to claim 1, wherein the Fc domain is a human Fc domain.

### Claim 19 (depends on 1)

The antigen binding molecule according to claim 1, wherein the Fc domain comprises a modification promoting the association of the first and the second subunit of the Fc domain.

### Claim 20 (depends on 1)

The antigen binding molecule according to claim 1, wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor and/or effector function.

### Claim 21 (depends on 1)

The antigen binding molecule according to claim 1, wherein
the first cytokine receptor-binding domain is fused at its C-terminus to the N-terminus of VH1 or VL1 of the first target-binding domain, and the first target-binding domain is fused at its N-terminus of VH1 or VL1 to the C-terminus of the first Fc domain subunit, and the second cytokine receptor-binding domain is fused at its C-terminus to the N-terminus of VH2 or VL2 of the second target-binding domain, and the second target-binding domain is fused at its C-terminus of CH12 or CL1 to the N-terminus of the second Fc domain subunit.

### Claim 22 (depends on 1)

The antigen binding molecule according to claim 1, comprising
a) a first polypeptide comprising in order from the N-terminus to C-terminus a first Fc domain subunit, a VH1 and a CH11, a second polypeptide comprising in order from the N-terminus to C-terminus a the first cytokine receptor-binding domain, a VL1 and a CL1, a third polypeptide comprising in order from the N-terminus to C-terminus a VL2, a CH12 and a second Fc domain subunit, and a fourth polypeptide comprising in order from the N-terminus to C-terminus a the second cytokine receptor-binding domain, a VH2 and a CL2; or
b) a first polypeptide comprising in order from the N-terminus to C-terminus a first Fc domain subunit, a VL1 and a CH11, a second polypeptide comprising in order from the N-terminus to C-terminus a the first cytokine receptor-binding domain, a VH1 and a CL1, a third polypeptide comprising in order from the N-terminus to C-terminus a VH2, a CH12 and a second Fc domain subunit, and a fourth polypeptide comprising in order from the N-terminus to C-terminus a the second cytokine receptor-binding domain, a VL2 and a CL2; or
c) a first polypeptide comprising in order from the N-terminus to C-terminus a first Fc domain subunit, a VL1 and a CL1, a second polypeptide comprising in order from the N-terminus to C-terminus a the first cytokine receptor-binding domain, a VH1 and a CH11, a third polypeptide comprising in order from the N-terminus to C-terminus a VL2, a CH12 and a second Fc domain subunit, and a fourth polypeptide comprising in order from the N-terminus to C-terminus a the second cytokine receptor-binding domain, a VH2 and a CL2; or
d) a first polypeptide comprising in order from the N-terminus to C-terminus a first Fc domain subunit, a VH1 and a CL1, a second polypeptide comprising in order from the N-terminus to C-terminus a the first cytokine receptor-binding domain, a VL1 and a CH11, a third polypeptide comprising in order from the N-terminus to C-terminus a VH2, a CH12 and a second Fc domain subunit, and a fourth polypeptide comprising in order from the N-terminus to C-terminus a the second cytokine receptor-binding domain, a VL2 and a CL2; or
e) a first polypeptide comprising in order from the N-terminus to C-terminus a first Fc domain subunit, a VH1 and a CH11, a second polypeptide comprising in order from the N-terminus to C-terminus a the first cytokine receptor-binding domain, a VL1 and a CL1, a third polypeptide comprising in order from the N-terminus to C-terminus a the second cytokine receptor-binding domain, a VL2, a CH12 and a second Fc domain subunit, and a fourth polypeptide comprising in order from the N-terminus to C-terminus a VH2 and a CL2; or
f) a first polypeptide comprising in order from the N-terminus to C-terminus a first Fc domain subunit, a VL1 and a CH11, a second polypeptide comprising in order from the N-terminus to C-terminus a the first cytokine receptor-binding domain, a VH1 and a CL1, a third polypeptide comprising in order from the N-terminus to C-terminus a the second cytokine receptor-binding domain, a VH2, a CH12 and a second Fc domain subunit, and a fourth polypeptide comprising in order from the N-terminus to C-terminus a VL2 and a CL2; or
g) a first polypeptide comprising in order from the N-terminus to C-terminus a first Fc domain subunit, a VL1 and a CL1, a second polypeptide comprising in order from the N-terminus to C-terminus a the first cytokine receptor-binding domain, a VH1 and a CH11, a third polypeptide comprising in order from the N-terminus to C-terminus a the second cytokine receptor-binding domain, a VL2, a CH12 and a second Fc domain subunit, and a fourth polypeptide comprising in order from the N-terminus to C-terminus a VH2 and a CL2; or
h) a first polypeptide comprising in order from the N-terminus to C-terminus a first Fc domain subunit, a VH1 and a CL1, a second polypeptide comprising in order from the N-terminus to C-terminus a the first cytokine receptor-binding domain, a VL1 and a CH11, a third polypeptide comprising in order from the N-terminus to C-terminus a the second cytokine receptor-binding domain, a VH2, a CH12 and a second Fc domain subunit, and a fourth polypeptide comprising in order from the N-terminus to C-terminus a VL2 and a CL2;
wherein VH1, VL1, CH11, and CL1 form the first target-binding domain and VH2, VL2, CH12, and CL2 form the second target-binding domain.

### Claim 23 (depends on 1)

The antigen binding molecule according to claim 1, wherein the first target-binding domain and the second target-binding domain specifically bind to FAP and the first and second cytokine receptor subunits are subunits of the IFNγ receptor complex.

### Claim 24 (depends on 1)

The antigen binding molecule according to claim 1, comprising
a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 50, a second polypeptide comprising the amino acid sequence of SEQ ID NO: 48, a third polypeptide comprising the amino acid sequence of SEQ ID NO: 51 and a fourth polypeptide comprising the amino acid sequence of SEQ ID NO: 49; or
b) a first polypeptide comprising an amino acid sequence of SEQ ID NO: 99, a second polypeptide comprising an amino acid sequence of SEQ ID NO: 97, a third polypeptide comprising an amino acid sequence of SEQ ID NO: 100, and a fourth polypeptide comprising an amino acid sequence of SEQ ID NO: 98; or
c) a first polypeptide comprising an amino acid sequence of SEQ ID NO: 103, a second polypeptide comprising an amino acid sequence of SEQ ID NO: 101, a third polypeptide comprising an amino acid sequence of SEQ ID NO: 104, and a fourth polypeptide comprising an amino acid sequence of SEQ ID NO: 102; or
d) a first polypeptide comprising an amino acid sequence of SEQ ID NO: 107, a second polypeptide comprising an amino acid sequence of SEQ ID NO: 105, a third polypeptide comprising an amino acid sequence of SEQ ID NO: 108, and a fourth polypeptide comprising an amino acid sequence of SEQ ID NO: 106; or
e) a first polypeptide comprising an amino acid sequence of SEQ ID NO: 99, a second polypeptide comprising an amino acid sequence of SEQ ID NO: 109, a third polypeptide comprising an amino acid sequence of SEQ ID NO: 100, and a fourth polypeptide comprising an amino acid sequence of SEQ ID NO: 110; or
f) a first polypeptide comprising an amino acid sequence of SEQ ID NO: 107, a second polypeptide comprising an amino acid sequence of SEQ ID NO: 111, a third polypeptide comprising an amino acid sequence of SEQ ID NO: 113, and a fourth polypeptide comprising an amino acid sequence of SEQ ID NO: 112; or
g) a first polypeptide comprising an amino acid sequence of SEQ ID NO: 99, a second polypeptide comprising an amino acid sequence of SEQ ID NO: 114, a third polypeptide comprising an amino acid sequence of SEQ ID NO: 100, and a fourth polypeptide comprising an amino acid sequence of SEQ ID NO: 115; or
h) a first polypeptide comprising an amino acid sequence of SEQ ID NO: 107, a second polypeptide comprising an amino acid sequence of SEQ ID NO: 116, a third polypeptide comprising an amino acid sequence of SEQ ID NO: 108, and a fourth polypeptide comprising an amino acid sequence of SEQ ID NO: 117.

### Claim 25 (depends on 1)

The antigen binding molecule according to claim 1, wherein the first target-binding domain and the second target-binding domain specifically bind to PD-1 and the first and second cytokine receptor subunits are subunits of the IL-2 receptor complex.

### Claim 26 (depends on 1)

The antigen binding molecule according to claim 1, comprising a first polypeptide comprising an amino acid sequence of SEQ ID NO: 123, a second polypeptide comprising an amino acid sequence of SEQ ID NO: 122, a third polypeptide comprising an amino acid sequence of SEQ ID NO: 124, and a fourth polypeptide comprising an amino acid sequence of SEQ ID NO: 125.
